...
首页> 外文期刊>胸部外科 >Surgery for thymomas and thymic carcinomas; treatment results in terms of WHO histologic typing, Masaoka staging system, and p53 expression
【24h】

Surgery for thymomas and thymic carcinomas; treatment results in terms of WHO histologic typing, Masaoka staging system, and p53 expression

机译:胸腺瘤和胸腺癌手术;根据WHO组织学分型,正冈分期系统和p53表达进行治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Forty thymomas and thymic carcinomas were classified in terms of WHO histologic typing, Masaoka staging system, and p53 expression. In WHO histologic typing, type A, AB, B1, B2, B3, and C were 1, 10, 16, 5, 4, and 4 cases, respectively. In Masaoka staging system, I, II, III, and IV were 15, 9, 10, and 6 cases, respectively. Thirteen thymomas exhibited positive p53 expression and 27 did not. Type A and AB thymomas had more favorite prognosis than type B3 and C thymomas, and prognosis of type B1 and B2 was middle. Staging by the Masaoka system also correlated with survival rates. Patients who had p53-negative thymomas survived longer than those who had p53-positive thymomas. A treatment strategy for thymomas and thymic carcinomas should be made on the basis of WHO histologic typing, Masaoka staging system, and p53 expression.
机译:根据WHO组织学分型,正冈分期系统和p53表达对40例胸腺癌和胸腺癌进行了分类。在WHO组织学分型中,A,AB,B1,B2,B3和C型分别为1、10、16、5、4和4例。在Masaoka分期系统中,I,II,III和IV分别为15、9、10和6例。 13例胸腺瘤表现出p53阳性表达,而27例则没有。 A和AB型胸腺瘤比B3和C型胸腺瘤更喜欢预后,B1和B2型胸腺瘤的预后中等。 Masaoka系统的分期也与生存率相关。 p53阴性胸腺瘤患者的生存期长于p53阳性胸腺瘤患者。胸腺瘤和胸腺癌的治疗策略应根据WHO的组织学分型,正冈分期系统和p53表达来制定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号